Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size. The genes that are dysfunctional in muscular dystrophies are often extremely large, and current delivery methods can’t courier such substantial genetic loads into the body. A new technology, dubbed “StitchR,” surmounts this obstacle by delivering two halves of a gene separately; once in a cell, both DNA segments generate messenger RNAs (mRNAs) that join seamlessly together to restore expression of a protein that is missing or inactive in disease.
Published in the journal Science, StitchR — short for “stitch RNA” — restored expression of large therapeutic muscle proteins to normal levels in two different animal models of muscular dystrophy. StitchR enabled expression of the protein Dysferlin, which is lacking in individuals with limb girdle muscular dystrophy type 2B/R2, as well as the protein Dystrophin, which is absent in patients with Duchenne muscular dystrophy.
Duchenne muscular dystrophy is the most common early onset form of muscular dystrophy; many boys become wheelchair bound in their teens and die in their twenties. People with limb girdle muscular dystrophy experience weakness and wasting in the shoulder, hip, and thigh muscles, and often have difficulty standing, moving, and doing everyday tasks.
“Gene therapy is a powerful tool for delivering a healthy gene copy back to a patient’s cells to correct genetic diseases, but the vectors used to deliver this information are small, which has so far precluded their use for treating a whole host of diseases caused by mutations in large genes,” said Douglas M. Anderson, PhD, lead study author and assistant professor of Medicine in the Aab Cardiovascular Research Institute at the University of Rochester School of Medicine and Dentistry (SMD). “Instead of delivering the full gene in a single vector, which isn’t possible, we’ve developed an efficient dual vector system where two halves of a gene are delivered separately but come together to reconstitute the large mRNA in the affected tissues.”
The technology first arose from a serendipitous observation made in the lab several years ago, that when two separate mRNAs were cut by small RNA sequences called ribozymes, they became seamlessly ligated (joined) and translated into full-length protein. The team found that when ribozymes cleave or cut RNA, they leave ends that are recognized by a natural repair pathway.
“Similar to when CRISPR enzymes are used to cut DNA, the CRISPR enzymes are just the scissors, and it’s a cell’s natural repair enzymes that glue the DNA back together,” noted Anderson, who is also a member of the University of Rochester Center for RNA Biology. “We think something similar is happening here, but for RNA. The ribozymes are acting as the scissors and the cell’s natural repair pathways are able to join the two RNAs back together. It’s remarkable that two separate mRNAs are able to find themselves and that the process can be so efficient.”
The lab optimized efficiency of the process (over 900-fold from their initial experiments) and adapted the technology into a powerful gene delivery mechanism. When two halves of a large therapeutic gene are encoded into adeno-associated virus (AAV) vectors, which are the most commonly used vectors for gene therapy because they are safe and don’t cause disease in humans, the ribozymes cut the ends of the mRNAs and they subsequently join, forming a single, seamless mRNA capable of producing protein in a desired tissue.
The research team, including co-first author Sean Lindley, who recently received his PhD from the Anderson lab, found that the stitched mRNAs appear to behave essentially the same way as their natural full-length counterparts, effectively translating genetic information into functional proteins.
Self-cleaving ribozymes, which are essential for StitchR activity, are found naturally throughout the animal kingdom and are comprised of different families, which exhibit different cleavage activities. After testing numerous ribozyme families and sequences, they ultimately identified a formula that led to a high level of protein production and approached the levels achieved by genes expressed from just a single vector.
“Doug is extremely creative and detail oriented, and the fact that he’s worked out how two different pieces of mRNA can find one another in a cell and be joined seamlessly to create a functional mRNA is really exciting,” said Lynne E. Maquat, PhD, director of the UR Center for RNA Biology. “The concept sounds simple, but this required considerable bench work to optimize the molecules involved, ensure they are stable in cells, and make the process as efficient as possible.”
According to Anderson, StitchR can be coupled with many different types of vectors that are used to deliver or express a gene in cells and that it appears to work efficiently with any mRNA sequence, opening the door for its use in a wide range of diseases and applications. “StitchR is really plug and play at this point. The sequence requirements for StitchR are minimal, and we’ve now tested this with many different genes and sequences,” he said.
Another feature of this technology is that only the full-length protein is produced.
“Other dual vector approaches have been in development for decades but have been plagued by lack of efficiency and the production of less than full-length products. Because StitchR occurs at the level of RNA, we can control and ensure that only the full-length protein product gets made. This differentiates StitchR from other dual vector technologies, for example inteins, a protein-ligation technology, which can be efficient but requires the expression of smaller protein fragments that may have unknown effects in a cell,” added Anderson.
“It’s been a long but fulfilling process to go from an initial research observation to a therapeutic application, but that’s always been a major goal of our lab, and I think the promise of basic research. With StitchR and other tools we are working towards treatments for some of the most debilitating genetic diseases on the planet, many of which have no current treatments or cures,” said Anderson.
The lab is now in the process of forming collaborations with other research labs and generating StitchR vectors to treat numerous diseases caused by large genes, of which there are thousands.
In addition to Anderson and Lindley, SMD staff scientists Kadiam C. Venkata Subbaiah (co-first author), Pornthida Poosala, FNU Priyanka and technicians William Richardson and Tamlyn Thomas contributed to the work, as well as CANbridge Pharmaceuticals scientists Yijie Ma, Leila Jalinous, and Jason A. West. The work was funded by the University of Rochester, Jain Foundation, CANbridge Phamaceuticals, and Scriptr Global, Inc. Anderson is a co-founder of Scriptr Global, Inc. and holds several US and foreign patent applications for his research related to StitchR and other RNA-based technologies. Scriptr licensed the StitchR technology from the University of Rochester.
Source link
